One difference emerging from the vaccine studies compared with enhanced activity of the CMS in controlling both mucosal immune integrity and intrabronchial infection is the role of IgA antibodies in protection against certain gut infections such as cholera [46]. The gene discussed is CD79A; the disease is vibrio infectious disease.